問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberCS001P3

2010-12-01 - 2020-12-07

Phase III

Terminated6

Suspended3

ICD-10D37.01

Neoplasm of uncertain behavior of lip

ICD-10D37.02

Neoplasm of uncertain behavior of tongue

ICD-10D37.04

Neoplasm of uncertain behavior of the minor salivary glands

ICD-10D37.05

Neoplasm of uncertain behavior of pharynx

ICD-10D37.09

Neoplasm of uncertain behavior of other specified sites of the oral cavity

ICD-9235.1

Neoplasm of uncertain behavior of lip, oral cavity and pharynx

  • Trial Applicant

    Orient EuroPharma Co., Ltd. 

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/19

Investigators and Locations

Principal Investigator 侯勝博 Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Suspended

Principal Investigator Pei-Jen Lou Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Ku-How Fang Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 陳穆寬 Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Sen-Tien Tsai Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 簡志彥 Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Suspended

Principal Investigator Ming-Hsui Tsai Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 陳培榕 Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Chen-Chi Wang Division of Otolaryngology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Suspended

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    88 participants

  • Global

    1273 participants